Education
About Us
Working with TipRanks
Follow Us
Cyclo Therapeutics Inc (CYTH)
NASDAQ:CYTH
Total Valuation
Cyclo Therapeutics has a market cap or net worth of $20.73M. The enterprise value is ―.
Market Cap$20.73M
Enterprise Value―
Share Statistics
Cyclo Therapeutics has 28,614,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,614,000
Owned by Insiders55.06%
Owned by Institutions4.47%
Financial Efficiency
Cyclo Therapeutics’s return on equity (ROE) is -4.22 and return on invested capital (ROIC) is -346.28%.
Return on Equity (ROE)-4.22
Return on Assets (ROA)-1.51
Return on Invested Capital (ROIC)-346.28%
Return on Capital Employed (ROCE)-4.20
Revenue Per Employee134.55K
Profits Per Employee-2.51M
Employee Count8
Asset Turnover0.08
Inventory Turnover0.39
Valuation Ratios
The current PE Ratio of Cyclo Therapeutics is -1.29. Cyclo Therapeutics’s PEG ratio is 0.36.
PE Ratio-1.29
PS Ratio23.13
PB Ratio-1.49
Price to Fair Value5.46
Price to FCF-0.76
Price to Operating Cash Flow-0.89
PEG Ratio0.36
Income Statement
In the last 12 months, Cyclo Therapeutics had revenue of 1.08M and earned -20.06M in profits. Earnings per share was -1.23.
Revenue1.08M
Gross Profit977.95K
Operating Income-20.05M
Pretax Income-20.06M
Net Income-20.06M
EBITDA-20.03M
Earnings Per Share (EPS)-1.23
Cash Flow
In the last 12 months, operating cash flow was -22.52M and capital expenditures -2.42K, giving a free cash flow of -26.37M billion.
Operating Cash Flow-22.52M
Free Cash Flow-26.37M
Free Cash Flow per Share-0.92
Dividends & Yields
Cyclo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.48
52-Week Price Change-44.19%
50-Day Moving Average0.79
200-Day Moving Average0.86
Relative Strength Index (RSI)47.87
Average Volume (3m)119.08K
Important Dates
Cyclo Therapeutics upcoming earnings date is May 14, 2025, TBA Not Confirmed.
Last Earnings DateMar 17, 2025
Next Earnings DateMay 14, 2025
Ex-Dividend Date―
Financial Position
Cyclo Therapeutics as a current ratio of 1.45, with Debt / Equity ratio of -0.20%
Current Ratio1.45
Quick Ratio1.42
Debt to Market Cap0.00
Net Debt to EBITDA0.41
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cyclo Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cyclo Therapeutics EV to EBITDA ratio is -0.89, with an EV/FCF ratio of -1.10.
EV to Sales16.49
EV to EBITDA-0.89
EV to Free Cash Flow-1.10
EV to Operating Cash Flow-1.10
Balance Sheet
Cyclo Therapeutics has $928.01K in cash and marketable securities with $27.26K in debt, giving a net cash position of -$900.75K billion.
Cash & Marketable Securities$928.01K
Total Debt$27.26K
Net Cash-$900.75K
Net Cash Per Share-$0.03
Tangible Book Value Per Share$0.29
Margins
Gross margin is -205.60%, with operating margin of -1862.69%, and net profit margin of -1863.36%.
Gross Margin-205.60%
Operating Margin-1862.69%
Pretax Margin-1863.36%
Net Profit Margin-1863.36%
EBITDA Margin-1860.90%
EBIT Margin-1862.69%
Analyst Forecast
The average price target for Cyclo Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-8.52%
EPS Growth Forecast46.35%